Brief: Denali Therapeutics Announces Completion Of Enrollment For Regimen G Evaluating eIF2B Agonist DNL343 In Phase 2/3 HEALEY ALS Platform Trial
01/05/2024 13:30
May 1 (Reuters) - Denali Therapeutics Inc DNLI.O :
* DENALI THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT FOR
REGIMEN G EVALUATING EIF2B AGONIST DNL343 IN THE PHASE 2/3
HEALEY ALS PLATFORM TRIAL
Source text for Eikon: ID:nGNX1cgjvm
Further company coverage: DNLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers